Healome Therapeutics closes £2 million seed funding led by Empirical Ventures for its eye surface disease treatment technology, with contributions from various investors.
Amount Raised
£2 Million
Round Type
Seed
BirminghamBiotechnologyHealth CareTherapeuticsInvestors
Description
Healome Therapeutics has successfully closed an oversubscribed seed funding round of £2 million. The investment, led by Empirical Ventures, will support preclinical development, production capacity, and regulatory pathways. With this funding, Healome aims to prepare for its first human trials slated for 2027. The company's innovative eye drop matrix addresses poor retention in traditional eye drops.
Quick answer
Healome Therapeutics raised £2 Million in a Seed round, dated July 7, 2026. Investors: Debra Research, Cure Eb, Oshen Bio, SFC Capital and Empirical Ventures. Healome Therapeutics is based in Birmingham, England, United Kingdom.
- How much did Healome Therapeutics raise?
- Healome Therapeutics raised £2 Million in a Seed round on July 7, 2026.
- Who invested in Healome Therapeutics?
- Debra Research, Cure Eb, Oshen Bio, SFC Capital and Empirical Ventures are named as investors in this round.
- What does Healome Therapeutics do?
- Healome Therapeutics is a spin-off from the University of Birmingham developing an exclusive eye drop matrix technology aimed at treating surface eye diseases.
- Where is Healome Therapeutics based and how big is it?
- Healome Therapeutics is based in Birmingham, England, United Kingdom. Fundz records about 5 employees.
- Who are the decision-makers at Healome Therapeutics?
- Fundz holds 1 contact at Healome Therapeutics, including the Chief Scientific Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Healome Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Amylyx Pharmaceuticals raised $500M (Post-IPO Equity) on August 20, 2026.
- Kynexis raised $46M (Series A) on August 19, 2026.
- Abcuro raised $66M (Series D) on August 18, 2026.
- bioAffinity Technologies raised $4M (Post-IPO Equity) on August 14, 2026.
- Apollomics raised $10M on August 14, 2026.
- Khartis Therapeutics raised $50M (Series B) on August 13, 2026.
Who to call at Healome Therapeutics, and when
A new round usually means Healome Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Healome Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Healome Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Healome Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Healome Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Healome Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.